OakChart

Prelude Therapeutics Inc

PRLDHealthcare·Biotechnology·USA·Small·NASD·Nov 11 • 10:45 AM ET

3.97+0.21 (5.72%)
2026-11-11 16:46 CET
Market cap
300.06 USD m
Revenue, TTM
22.42 USD m
Net income, TTM
-60.49 USD m
Free cash flow, TTM
-33.26 USD m
EPS diluted, TTM
-0.79
P/E
-
Compare

Price

PRLD against its 20, 50 and 200-day averages
2050200beat
2.004.006.001.8M3.7MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26PRLDclose 3.9820-day 3.7250-day 4.08200-day 4.083.9852w high

41.8% under the 52-week high of 6.83 on 24 Aug 2026. 52-week low 1.21 on 11 Nov 2025. Last 15 sessions, 27.2% high to low

Profile

PRLD
52-week range, 49% of the way up
1.216.83

Prelude Therapeutics, Inc. is a clinical-stage oncology company, which engages in the development of novel precision cancer medicines. It also focuses on the design and development of small molecule agents for cancer medicines. The company was founded by Krishna Vaddi in 2016 and is headquartered in Wilmington, DE.

IndexRUT
Employees79
IPOSep 25, 2020
Beta1.19
ATR, 14d0.32
Rel volume0.54
Short float9.34%
Insider own43.95%
Inst own45.25%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap317.22M
Enterprise Value183.11M
Income-60.49M
Sales22.42M
Book/sh1.68
Cash/sh1.90
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees79
IPOSep 25, 2020

Ratios

P/E-
Forward P/E-
PEG-
P/S14.15
P/B2.37
P/C2.09
P/FCF-
EV/EBITDA-
EV/Sales8.17
Quick Ratio4.07
Current Ratio4.07
Debt/Eq0.13
LT Debt/Eq0.11
Option/ShortYes / Yes

Earnings

EPS (ttm)-0.79
EPS next Y-0.48
EPS next Q0.01
EPS this Y68.84%
EPS next Y-18.41%
EPS next 5Y57.36%
EPS past 3/5Y19.05% 0.15%
Sales past 3/5Y- -
EPS Y/Y TTM55.73%
Sales Y/Y TTM220.34%
EPS Q/Q65.57%
Sales Q/Q-
EarningsAug 11 BMO
EPS/Sales Surpr.28.83% -

Ownership

Insider Own43.95%
Insider Trans0.00%
Inst Own45.25%
Inst Trans18.04%
ROA-39.76%
ROE-57.73%
ROIC-40.70%
Gross Margin92.92%
Oper. Margin-300.56%
Profit Margin-269.75%
SMA206.81%
SMA50-2.53%
SMA200-2.65%
Trades-

Technical

Shs Outstand65.03M
Shs Float44.73M
Short Float9.34%
Short Ratio8.47
Short Interest4.18M
52W High6.83 -41.80%
52W Low1.21 228.51%
Volatility11.48% 9.12%
ATR (14)0.32
RSI (14)53.01
Beta1.19
Rel Volume0.54
Avg Volume492.96K
Volume62,497

Performance

Perf Week-2.57%
Perf Month11.66%
Perf Quarter-25.84%
Perf Half Y-14.70%
Perf YTD37.07%
Perf Year194.44%
Perf 3Y32.06%
Perf 5Y-76.28%
Perf 10Y-
Recom1.00
Target Price9.20
Prev Close3.76
Price3.97
Change %5.72%

Analyst ratings

latest 10 of 20
DateActionAnalystRating changeTargetImplied
Sep 17, 2026InitiatedJJP MorganOverweight$12+201.9%
May 04, 2026InitiatedDD. Boral CapitalBuy$9+126.4%
Sep 19, 2024UpgradeHH.C. WainwrightNeutral → Buy$5+25.8%
Jun 20, 2024DowngradeBBarclaysEqual Weight → Underweight$3-24.5%
Mar 13, 2024InitiatedJJMP SecuritiesMkt Outperform$7+76.1%
Feb 20, 2024DowngradeHH.C. WainwrightBuy → Neutral$5+25.8%
Dec 19, 2023DowngradeMMorgan StanleyEqual-Weight → Underweight$10 → $4+0.6%
Nov 21, 2022DowngradeBBofA SecuritiesNeutral → Underperform$8 → $6+50.9%
Sep 09, 2022DowngradeMMorgan StanleyOverweight → Equal-Weight$19 → $11+176.7%
Jul 29, 2022InitiatedJJefferiesBuy$9+126.4%

Peers

Mkt cap
TickerCompanyMkt cap
DMRADamora Therapeutics Inc1.53B
INCYIncyte Corp24.55B
OLMAOlema Pharmaceuticals Inc631.74M
PTGXProtagonist Therapeutics Inc8.70B
GERNGeron Corp637.93M
ARVNArvinas Inc445.96M
CCCCC4 Therapeutics Inc396.58M
KPTIKaryopharm Therapeutics Inc0.39M
KYMRKymera Therapeutics Inc11.51B
PFEPfizer Inc166.71B

Insider trading

2 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Bonita David PDirectorApr 21 '26Buy4.442,815,31512,499,99911,808,945Apr 23 06:50 PM
ORBIMED ADVISORS LLCDirectorApr 21 '26Buy4.442,815,31512,499,99911,808,945Apr 23 06:48 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
IWMiShares Russell 2000 Index FundAUM: 77.38B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IWOiShares Russell 2000 Growth ETFAUM: 14.06B
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B
IWCiShares Micro-Cap ETFAUM: 1.22B
BUSMEA Bridgeway Ultra-Small Company Market ETFAUM: 111.21M
VTWGVanguard Russell 2000 Growth Index ETFAUM: 1.41B
AVSCAvantis U.S Small Cap Equity ETFAUM: 3.23B
DFMCU.S. Micro Cap Portfolio ETF Class Shares-

News

latest 14 of 206
  • Prelude Therapeutics to Participate in the Chardan Healthcare Conference (GlobeNewswire)
  • Prelude Therapeutics Teams Up With Lilly To Test Experimental Breast Cancer Drug In Phase 1 Trial (Stocktwits)
  • Prelude Announces Clinical Trial Collaboration and Supply Agreement with Lilly to Evaluate KAT6A Selective Degrader PRT13722 in Combination with Verzenio and Inluriyo in Patients with HR+/HER2- Breast Cancer (GlobeNewswire)
  • Prelude Therapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference (GlobeNewswire)
  • Prelude Therapeutics Receives FDA Clearance of Investigational New Drug (IND) Application for PRT13722, Its First-in-Class Oral KAT6A Selective Degrader (GlobeNewswire) -8.25%
  • Loading…
  • Sellas Experimental Drug SLS009 Appears To Be Leading The CDK9 Race, Says Alliance Global Analyst Sees About 200% Upside Potential (Stocktwits) +7.71%
  • Prelude Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update (GlobeNewswire) +10.14%
  • Prelude Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update (GlobeNewswire)
  • Prelude Therapeutics Announces Pricing of $90.0 Million Underwritten Offering (GlobeNewswire)
  • Prelude Therapeutics Presents Preclinical Data from Development Candidate, PRT13722, a First-in-Class, Orally Bioavailable, Potent and Highly Selective KAT6A Degrader at American Association for Cancer Research (AACR) Annual Meeting 2026 (GlobeNewswire)
  • Prelude Therapeutics Announces the Appointment of Charles Morris, M.D. as Chief Medical Officer (GlobeNewswire) +25.45%
  • Prelude Therapeutics Announces Acceptance of Preclinical Abstract for PRT13722, a First-in-Class Oral KAT6A Selective Degrader at the 2026 AACR Annual Meeting (GlobeNewswire) -9.04%
  • Prelude Therapeutics price target raised to $6 from $3 at Citizens (TipRanks) +5.83%

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q22026-08-11-0.140-0.197-0.1405.700.003
2026Q12026-05-12-0.130-0.253-0.1264.580.004
2025Q42026-03-10-0.200-0.030-0.2615.6120.502
2025Q32025-11-12-0.260-0.370-0.2596.500.003
2025Q22025-08-14-0.410-0.438-0.4110.000.004
2025Q12025-05-06-0.420-0.467-0.4220.000.003
2024Q42025-03-10-0.370-0.463-0.5214.000.003
2024Q32024-11-06-0.430-0.472-0.4253.000.005
2024Q22024-08-12-0.460-0.430-0.4590.000.004
2024Q12024-05-07-0.420-0.484-0.4150.000.004
2023Q42024-02-15-0.450-0.490-0.6020.00-3
2023Q32023-11-01-0.450-0.583-0.453-0.003
2023Q22023-08-03-0.540-0.633-0.5410.000.003
2023Q12023-05-08-0.580-0.685-0.5810.000.004
2022Q42023-03-15-0.600-0.628-0.5980.000.005
2022Q32022-11-14-0.630-0.636-0.6310.000.005

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2020FY-4.560-3.695-1.3030.000.00
2021FY-2.430-2.413-2.3460.000.00
2022FY-2.440-2.474-2.4370.000.00
2023FY-2.020-2.040-2.0190.000.00
2024FY-1.680-1.773-1.6787.001.50
2025FY-1.290-1.250-1.29012.1417.50
2026FY--0.402--43.15
2027FY--0.476--36.33
2028FY--0.100--100
2029FY-0.220--100
2030FY-0.640--100

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q3S2026-10-2541029.005.00100
2026Q3S2026-10-1242029.005.00100
2026Q3S2026-10-0941027.750.00100
2026Q3S2026-09-1641027.750.00100
2026Q3S2026-08-1131035.330.00100
2026Q3S2026-07-2130033.330.00100
2026Q3S2026-05-1440025.000.00100
2026Q3S2026-05-1230033.330.00100
2026Q3S2026-04-2430033.330.00100
2026Q3S2026-03-1020050.000.00100
2026Q3S2025-12-3120050.000.00100
2026Q3S2025-11-1230033.330.00100
2026Q3S2025-11-1130033.330.00100
2026Q3S2025-11-1030033.330.00100

Estimate history

EPS, annual-0.336-0.631-1.303-2.346-2.437-2.019-1.678-1.293-0.7878
Period20182019202020212022202320242025TTM
EPS, quarterly-0.459-0.425-0.521-0.422-0.411-0.259-0.261-0.126-0.142
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Sales, annual000000712.1422.42
Period20182019202020212022202320242025TTM
Sales, quarterly034006.55.644.585.704
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Shares, annual43.70343.70343.70647.60247.89954.91455.14962.95479.757
Period20182019202020212022202320242025MRQ
Shares, quarterly55.00855.02855.14956.45456.59456.662.95463.01879.757
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue22.4212.147.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A1.591.711.771.173.042.240.540.380.15
Gross Profit20.8410.435.23-1.17-3.04-2.24-0.54-0.38-0.15
Selling, General and Administrative Excl. Other88.23115.00144.94131.11120.50111.4958.2227.7314.83
Research and Development69.4394.30118.00103.3992.8986.7848.1824.2812.62
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-67.40-104.57-139.71-132.28-123.54-113.73-58.76-28.11-14.97
Interest Expense-0.00-0.000.000.000.00--
Unusual Expense0.000.000.000.000.000.000.000.000.00
Net Income Before Taxes-60.49-99.50-127.17-121.83-115.44-111.69-56.93-27.57-14.68
Income Taxes0.000.000.000.000.000.000.000.000.00
Consolidated Net Income-60.49-99.50-127.17-121.83-115.44-111.69-56.93-27.57-14.68
Net Income From Continuing Operations-60.49-99.50-127.17-121.83-115.44-111.69-56.93-27.57-14.68
Net Income-60.49-99.50-127.17-121.83-115.44-111.69-56.93-27.57-14.68
EPS (Recurring)-0.61-1.29-1.68-2.02-2.44-2.35-1.30-0.63-0.34
EPS (Basic, Before Extraordinaries)-0.79-1.29-1.68-2.02-2.44-2.35-1.30-0.63-0.34
EPS (Diluted)-0.79-1.29-1.68-2.02-2.44-2.35-1.30-0.63-0.34
EBITDA-65.81-102.86-137.94-131.11-120.50-111.49-58.22-27.73-14.83
Non-Operating Income (Expense)6.915.0712.5410.458.102.041.830.540.29
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense8.2911.9121.3425.6225.1420.935.580.850.18
Price To Sales Ratio23.3918.3813.81------
Gross Margin92.9285.9174.69------
Operating Margin-300.56-861.33-1,995.91------
Net Margin-269.75-819.59-1,816.76------
Shares Outstanding79.7662.9555.1554.9147.9047.6043.7143.7043.70
Market Capitalization300.06300.0670.17234.11288.99587.543,126.983,296.55-

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q12024Q42024Q3
Total Revenue5.704.585.646.500.000.004.003.00
Cost of Goods Sold Incl. D&A0.350.390.420.420.430.430.490.41
Gross Profit5.354.195.226.08-0.43-0.433.512.60
Selling, General and Administrative Excl. Other20.8018.3722.5726.4931.7634.1737.3436.97
Research and Development16.1313.6017.9921.7125.7828.8231.6229.46
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-15.45-14.18-17.35-20.42-32.19-34.61-33.83-34.38
Interest Expense0.00-0.000.000.00---
Unusual Expense0.000.000.000.000.000.000.000.00
Net Income Before Taxes-13.92-10.38-16.46-19.73-31.23-32.09-28.73-32.27
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-13.92-10.38-16.46-19.73-31.23-32.09-28.73-32.27
Net Income From Continuing Operations-13.92-10.38-16.46-19.73-31.23-32.09-28.73-32.27
Net Income-13.92-10.38-16.46-19.73-31.23-32.09-28.73-32.27
EPS (Recurring)-0.14-0.13-0.26-0.26-0.41-0.42-0.52-0.43
EPS (Basic, Before Extraordinaries)-0.14-0.13-0.26-0.26-0.41-0.42-0.52-0.43
EPS (Diluted)-0.14-0.13-0.26-0.26-0.41-0.42-0.52-0.43
EBITDA-15.10-13.79-16.93-19.99-31.76-34.17-33.34-33.97
Non-Operating Income (Expense)1.533.790.890.690.962.525.102.10
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense2.032.001.842.423.813.833.775.93
Price To Sales Ratio23.3916.8815.0410.448.798.3410.0552.34
Gross Margin93.8191.4692.5993.46--87.7886.50
Operating Margin-270.93-309.54-307.59-314.12---845.78-1,145.87
Net Margin-244.06-226.75-291.79-303.46---718.28-1,075.70
Shares Outstanding79.7663.0262.9556.6056.5956.4555.1555.03
Market Capitalization300.06215.47164.1881.5045.7052.2370.17113.90

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Cash & Short Term Investments103.21133.61232.94201.73291.23218.3118.8815.60
Short Term Receivables0.000.000.000.000.000.000.000.00
Inventories0.000.000.000.000.000.000.000.00
Other Current Assets2.482.282.652.653.882.501.340.00
Total Current Assets105.69135.90235.59204.38295.12220.8120.2215.60
Net Property, Plant & Equipment32.2835.4737.746.705.642.481.650.81
Total Investments and Advances3.234.044.044.044.040.000.000.00
Intangible Assets-----0.000.000.00
Other Assets0.110.110.295.380.300.300.000.00
Total Assets141.31175.51277.67220.50305.10223.5921.8716.41
Short Term Debt Incl. Current Port. of LT Debt2.742.701.481.831.740.000.260.00
Accounts Payable3.980.000.000.000.000.001.971.36
Other Current Liabilities46.2722.9420.3519.8717.4611.382.601.08
Total Current Liabilities52.9925.6421.8321.7019.2011.384.832.45
Long Term Debt15.0415.3215.410.000.000.000.000.00
Provision for Risks Charges0.000.000.000.000.000.000.000.00
Other Liabilities4.643.093.343.360.000.030.010.06
Total Liabilities72.6844.0640.5825.0619.2011.414.842.50
Non-Equity Reserves0.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.0066.4436.59
Common Equity68.64131.46237.09195.44285.90212.18-49.41-22.69
Total Shareholders Equity68.64131.46237.09195.44285.90212.1817.0313.90
Accumulated Minority Interest0.000.000.000.000.000.000.000.00
Total Equity68.64131.46237.09195.44285.90212.1817.0313.90
Total Liabilities & Stockholders Equity141.31175.51277.67220.50305.10223.5921.8716.41
Book Value Per Share1.092.384.324.086.014.85-1.13-0.52
Tangible Book Value Per Share1.092.384.324.086.014.85-1.13-0.52
Full-Time Employees7913112812211668--
Price to Book Ratio2.240.450.981.332.0714.7414.44-
Return on Assets-62.81-56.12-48.91-43.93-42.25-46.39-144.06-
Return on Equity-99.45-69.01-56.33-47.97-44.85-49.67-178.26-
Return on Invested Capital-118.90-86.64-48.25-59.07-39.07-26.83-161.88-105.60
Quick Ratio1.995.3010.799.4215.3719.414.186.37
Current Ratio1.995.3010.799.4215.3719.414.186.37

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-60.49-99.50-127.17-121.83-115.44-111.69-56.93-27.57-14.68
Depreciation1.591.711.771.173.042.240.540.380.15
Other Funds (Non Cash)8.9013.0818.3024.0827.7322.305.590.860.20
Funds from Operations-50.00-84.71-107.10-96.58-84.66-87.16-50.79-26.33-14.34
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital16.7528.414.22-10.480.933.624.620.671.38
Cash from Operating Activities-33.26-56.30-102.89-107.06-83.73-83.53-46.18-25.66-12.95
Capital Expenditures0.00-0.07-0.76-3.51-3.02-2.32-0.62-0.78-0.53
Net Assets From Acquisitions0.000.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.000.00
Purchase or Sale of Investments-77.2553.5390.95-31.1384.71-261.480.000.000.00
Purchase of Investments-156.71-100.87-52.69-221.63-119.22-261.480.000.000.00
Sale Or Maturity of Investments79.45154.39143.65190.50203.930.000.000.000.00
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities-77.2553.4690.19-34.6581.69-263.80-0.62-0.78-0.53
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock110.5225.040.33136.410.81164.90246.4929.8517.94
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock110.5225.040.33136.410.81164.90246.4929.8517.94
Proceedsfrom Stock Options110.4825.020.27136.370.43161.39246.3929.8517.94
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00-0.26-0.120.00
Change in Long Term Debt0.000.000.000.000.000.00-0.26-0.120.00
Issuance of Long Term Debt0.000.000.000.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00-0.26-0.120.00
Net Financing Active Other Cash Flow-0.07-0.02-0.05-0.020.000.000.000.000.00
Other Financing Activities Uses-0.07-0.02-0.05-0.020.000.000.000.000.00
Cash from Financing Activities110.4424.82-0.12136.400.81164.90246.2329.7317.94
Net Change in Cash-0.0621.97-12.82-5.31-1.22-182.44199.433.284.45
Free Cash Flow-33.26-56.37-103.65-110.58-86.75-85.85-46.80-26.45-13.48
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Cash & Short Term Investments151.7681.55103.2154.9673.2299.07
Short Term Receivables0.000.000.000.000.000.00
Inventories0.000.000.000.000.000.00
Other Current Assets3.143.042.483.373.663.33
Total Current Assets154.9084.59105.6958.3376.88102.40
Net Property, Plant & Equipment30.7931.5032.2833.0833.8934.70
Total Investments and Advances3.403.233.233.234.044.04
Other Assets0.270.310.110.110.110.11
Total Assets189.36119.64141.3194.75114.92141.26
Short Term Debt Incl. Current Port. of LT Debt2.782.762.742.732.712.65
Accounts Payable2.032.073.982.534.965.83
Other Current Liabilities33.2336.8946.2712.9313.2311.30
Total Current Liabilities38.0441.7252.9918.1920.9119.79
Long Term Debt14.8714.9615.0415.1315.2115.27
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities2.722.784.642.902.973.03
Total Liabilities55.6359.4672.6836.2239.0838.08
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity133.7360.1868.6458.5375.84103.18
Total Shareholders Equity133.7360.1868.6458.5375.84103.18
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity133.7360.1868.6458.5375.84103.18
Total Liabilities & Stockholders Equity189.36119.64141.3194.75114.92141.26
Book Value Per Share1.680.961.091.031.341.83
Tangible Book Value Per Share1.680.961.091.031.341.83
Full-Time Employees--79---
Price to Book Ratio2.243.142.801.070.440.32
Return on Assets-39.76-59.64-62.81-76.56-73.30-65.83
Return on Equity-57.73-95.25-99.45-103.99-96.33-81.44
Return on Invested Capital-9.37-13.82-19.67-26.78-34.30-27.09
Quick Ratio4.072.031.993.213.685.18
Current Ratio4.072.031.993.213.685.18

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Net Income-13.92-10.38-16.46-19.73-31.23-32.09
Depreciation0.350.390.420.420.430.43
Other Funds (Non Cash)2.102.002.042.763.984.29
Funds from Operations-11.46-8.00-14.00-16.54-26.81-27.36
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-4.11-13.6937.12-2.570.74-6.88
Cash from Operating Activities-15.57-21.6823.12-19.11-26.07-34.23
Capital Expenditures0.000.000.000.00-0.02-0.05
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments-65.508.50-60.3440.0911.5462.23
Purchase of Investments-89.970.00-66.740.00-24.66-9.46
Sale Or Maturity of Investments24.468.506.4040.0936.2071.70
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-65.508.50-60.3440.0911.5262.19
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock85.83-0.2624.950.000.090.00
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock85.83-0.2624.950.000.090.00
Proceedsfrom Stock Options85.75-0.2925.020.000.000.00
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow-0.01-0.05-0.01-0.01-0.00-0.01
Other Financing Activities Uses-0.01-0.05-0.01-0.01-0.00-0.01
Cash from Financing Activities85.82-0.3124.94-0.010.04-0.16
Net Change in Cash4.74-13.50-12.2820.97-14.5227.80
Free Cash Flow-15.57-21.6823.12-19.11-26.09-34.28

Revenue breakdown

Pharmaceutical Preparations2024: 7.00M 2025: 12.14M
United States2024: 7.00M 2025: 12.14M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-309.34%4.2M44.7M490.60K
2026-10-1511.40%5.1M44.7M482.41K
2026-09-3010.23%4.6M44.7M467.03K
2026-09-158.11%3.6M44.7M502.31K
2026-08-318.03%3.6M44.7M480.61K
2026-08-148.54%3.8M44.7M427.84K
2026-07-318.79%3.7M41.8M449.89K
2026-07-157.87%3.3M41.8M484.34K
2026-06-306.76%2.8M41.8M480.36K
2026-06-154.29%1.8M41.8M373.68K
2026-05-293.68%1.7M46.0M374.38K
2026-05-154.02%1.9M46.0M392.79K
2026-04-304.69%1.6M33.2M348.72K
2026-04-157.88%1.8M22.9M319.62K
2026-03-3110.12%2.3M22.9M351.13K
2026-03-139.93%2.3M22.9M438.06K
2026-02-2710.93%2.3M20.8M441.97K
2026-02-1311.44%2.4M20.8M451.46K
2026-01-309.98%2.1M20.8M1.52M
2026-01-158.07%1.7M20.8M1.48M

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call2.500.751.751.255.3743.000.000.836-0.0640.002
call5.000.050.400.263.12931.000.000.388-0.0400.002
call7.500.001.000.007.2480.000.000.505-0.0910.002
put2.500.000.050.108.8041000.00-0.153-0.0710.001
put5.000.901.900.004.7610.000.00-0.608-0.0390.002
put7.503.304.300.006.3100.000.00-0.694-0.0550.002

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-09-108-KCurrent report2026-09-10SEC
2026-08-1110-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-118-KCurrent report2026-08-11SEC
2026-07-08SCHEDULE 13GSEC
2026-06-104Statement of changes in beneficial ownership of securities2026-06-09SEC
2026-06-104Statement of changes in beneficial ownership of securities2026-06-09SEC
2026-06-104Statement of changes in beneficial ownership of securities2026-06-09SEC
2026-06-104Statement of changes in beneficial ownership of securities2026-06-09SEC
2026-06-104Statement of changes in beneficial ownership of securities2026-06-09SEC
2026-06-104Statement of changes in beneficial ownership of securities2026-06-09SEC
2026-06-108-KCurrent report2026-06-09SEC
2026-05-1210-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-05-128-KCurrent report2026-05-12SEC
2026-05-044Statement of changes in beneficial ownership of securities2026-05-01SEC
2026-04-29ARSAnnual report to security holders. 2025-12-31SEC
2026-04-29DEFA14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-04-29DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-06-09SEC
2026-04-28SCHEDULE 13GSEC
2026-04-284Statement of changes in beneficial ownership of securities2026-04-27SEC
2026-04-283Initial statement of beneficial ownership of securities2026-04-21SEC
2026-04-23SCHEDULE 13D/ASEC
2026-04-234Statement of changes in beneficial ownership of securities2026-04-21SEC
2026-04-234Statement of changes in beneficial ownership of securities2026-04-21SEC
2026-04-224Statement of changes in beneficial ownership of securities2026-04-21SEC
2026-04-22SCHEDULE 13D/ASEC
2026-04-218-KCurrent report2026-04-20SEC
2026-04-21424B5SEC
2026-04-208-KCurrent report2026-04-20SEC
2026-04-158-KCurrent report2026-04-15SEC
2026-04-153Initial statement of beneficial ownership of securities2026-04-15SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-0425.00M200
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
ORBIMED ADVISORS LLC17.23%
BAKER BROS. ADVISORS LP12.71%
RA CAPITAL MANAGEMENT, L.P.8.13%
Soleus Capital Management, L.P.4.24%
Kynam Capital Management, LP3.03%
VANGUARD CAPITAL MANAGEMENT LLC2.52%
BlackRock, Inc.2.26%
SPHERA FUNDS MANAGEMENT LTD.1.28%
TWO SIGMA INVESTMENTS, LP1.25%
ADAR1 Capital Management, LLC1.13%

Funds

Fund% owned
VANGUARD TOTAL STOCK MARKET INDEX FUND1.90%
iShares Russell 2000 ETF0.83%
VANGUARD EXTENDED MARKET INDEX FUND0.58%
Fidelity Small Cap Index Fund0.38%
iShares Russell 2000 Growth ETF0.33%
Fidelity Extended Market Index Fund0.24%
SIMT Tax-Managed Small/Mid Cap Fund0.23%
VANGUARD RUSSELL 2000 INDEX FUND0.20%
iShares Micro-Cap ETF0.12%
Fidelity Total Market Index Fund0.09%

OakChart. PRLD. Cached 15 minutes.